#SFHS2609082AOrder of April 9, 2026, amending the list of pharmaceutical specialties approved for collective and various public services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the list of approved pharmaceuticals for public use in France. It expands the coverage of the pharmaceutical product Rinvoq (upadacitinib) to include treatment for giant cell arteritis in specific cases requiring reduced steroid use, where no alternative treatment like tocilizumab is appropriate.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Rinvoq's coverage expanded for giant cell arteritis treatment.
- Focus on cases needing reduced steroid use.
- Implemented when no alternative treatment is suitable.
Obligations
What this law requires
Update the official list of pharmaceutical specialties approved for collective and various public services to include Rinvoq (upadacitinib) 15mg extended-release tablets with the new indication for giant cell arteritis treatment
Restrict Rinvoq coverage for giant cell arteritis to adult patients with documented corticoid-dependence at doses ≥7.5 mg/day of prednisone causing recurrent relapses
Restrict Rinvoq coverage for giant cell arteritis to patients requiring rapid and early reduction of corticotherapy due to corticoid intolerance or severe comorbidities (unbalanced complicated diabetes, severe mood/psychotic disorders, severe fracture osteoporosis, uncontrolled severe hypertension)
Ensure Rinvoq is prescribed only when tocilizumab or other appropriate therapeutic alternatives are not suitable or available for the patient
Publish this Order in the Journal officiel de la République française